Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IRWD Ironwood Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: IRWD
Price (delayed)
$0.6999
Market cap
$113.25M
P/E Ratio
69.99
Dividend/share
N/A
EPS
$0.01
Enterprise value
$624.17M
Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the
Highlights
The EPS has surged by 150% since the previous quarter and by 100% year-on-year
The net income has soared by 136% from the previous quarter and by 100% YoY
Ironwood Pharmaceuticals's gross profit has decreased by 21% YoY and by 7% QoQ
IRWD's revenue is down by 21% YoY and by 7% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.ironwoodpharma.com
Key stats
What are the main financial stats of IRWD
Market
Valuations
Earnings
Shares outstanding
161.81M
Market cap
$113.25M
Enterprise value
$624.17M
Price to earnings (P/E)
69.99
Price to book (P/B)
N/A
Price to sales (P/S)
0.32
EV/EBIT
6.35
EV/EBITDA
6.23
EV/Sales
1.78
Revenue
$351.41M
Gross profit
$351.41M
Operating income
$93.12M
Net income
$880,000
EBIT
$98.23M
EBITDA
$100.24M
Free cash flow
$103.41M
Per share
Balance sheet
Liquidity
EPS
$0.01
EPS diluted
$0.01
Free cash flow per share
$0.65
Book value per share
-$1.88
Revenue per share
$2.21
TBVPS
$2.19
Total assets
$350.91M
Total liabilities
$652.24M
Debt
$599.48M
Equity
-$301.34M
Working capital
$143.52M
Debt to equity
-1.99
Current ratio
4.69
Quick ratio
4.39
Net debt/EBITDA
5.1
Margins
Efficiency
Dividend
EBITDA margin
28.5%
Gross margin
100%
Net margin
0.3%
Operating margin
26.5%
Return on assets
0.2%
Return on equity
N/A
Return on invested capital
11.8%
Return on capital employed
31.5%
Return on sales
28%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IRWD stock price
How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-11.63%
1 week
-23.25%
1 month
-36.95%
1 year
-91.38%
YTD
-84.2%
QTD
-52.39%
Financial performance
How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$351.41M
Gross profit
$351.41M
Operating income
$93.12M
Net income
$880,000
Gross margin
100%
Net margin
0.3%
IRWD's net margin has surged by 143% since the previous quarter and by 100% year-on-year
The net income has soared by 136% from the previous quarter and by 100% YoY
IRWD's operating margin has surged by 112% year-on-year
The operating income has soared by 110% YoY but it has decreased by 6% from the previous quarter
Price vs fundamentals
How does IRWD's price correlate with its fundamentals
Growth
What is Ironwood Pharmaceuticals's growth rate over time
Valuation
What is Ironwood Pharmaceuticals stock price valuation
P/E
69.99
P/B
N/A
P/S
0.32
EV/EBIT
6.35
EV/EBITDA
6.23
EV/Sales
1.78
The EPS has surged by 150% since the previous quarter and by 100% year-on-year
The company's equity rose by 13% YoY and by 3.2% QoQ
IRWD's P/S is 92% below its 5-year quarterly average of 3.9 and 87% below its last 4 quarters average of 2.4
IRWD's revenue is down by 21% YoY and by 7% QoQ
Efficiency
How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has surged by 133% QoQ and by 100% YoY
The return on sales has surged by 114% year-on-year
Ironwood Pharmaceuticals's ROIC has soared by 111% YoY but it has decreased by 7% from the previous quarter
Dividends
What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IRWD.
Financial health
How did Ironwood Pharmaceuticals financials performed over time
The total assets is 46% less than the total liabilities
The quick ratio has increased by 32% since the previous quarter
Ironwood Pharmaceuticals's current ratio has increased by 30% from the previous quarter
IRWD's debt is down by 16% year-on-year and by 2.5% since the previous quarter
The company's equity rose by 13% YoY and by 3.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.